Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionTrexquant Investment LP
Latest Disclosed Ownership61,760 shares
Latest Disclosed Value $ 20,434,531
Trexquant Investment LP reports 130.96% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Trexquant Investment LP filed a 13F-HR form disclosing ownership of 61,760 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $17,644,832 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 26,741 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 130.96% during the quarter. The current value of the position is $16,088,480 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 61,760 35,019 130.96 20,435 92.18 0.1468
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26,741 14,345 115.72 10,634 88.13 0.0948
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,396 -8,147 -39.66 5,653 -15.62 0.0582
2025-08-12 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,543 20,543 6,699 0.0756
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -44,024 -100.00 0 -100.00
2025-02-12 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,024 -46,719 -51.48 10,359 -58.49 0.1207
2024-11-12 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 90,743 52,880 139.66 24,957 171.27 0.3159
2024-08-13 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 37,863 -59,112 -60.96 9,201 -36.52 0.1404
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 96,975 45,578 88.68 14,493 47.32 0.2889
2024-02-09 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 51,397 40,376 366.36 9,838 404.20 0.2214
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,021 11,021 1,952 0.0490
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -43,673 -100.00 0 -100.00
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,673 561 1.30 10,379 20.27 0.2943
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,112 43,112 8,629 0.3034
2022-08-11 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -21,496 -100.00 0 -100.00
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,496 21,496 3,510 0.1649
2021-05-13 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -6,393 -100.00 0 -100.00
2021-02-11 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,393 6,393 831 0.0880
2020-08-07 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -16,471 -100.00 0 -100.00
2020-05-08 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,471 10,522 176.87 1,793 161.75 0.1301
2020-02-12 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,949 214 3.73 685 48.59 0.0405
2020-02-18 2019-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 5,735 -8,858 -60.70 461 -56.47 0.0398
2019-11-08 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,735 -8,858 461 39,815.3810
2019-08-09 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,593 4,513 44.77 1,059 12.42 0.0953
2019-05-13 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,080 10,080 942 0.0669
2018-05-03 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -3,021 -100.00 0 -100.00
2018-02-08 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,021 3,021 384 0.0422
2016-05-11 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 0 0 0.0000
2016-02-10 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -27,859 -100.00 0 -100.00
2015-11-02 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,859 27,859 2,238 0.1926
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.